ReviewBMC infectious diseases2025
Janibacter melonis bacteremia following autologous stem cell mobilization in lymphoma: a case report and literature review.
Review in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInfection is a major cause of morbidity and mortality in patients with hematologic malignancies. Janibacter melonis is a rare opportunistic pathogen capable of causing bacteremia even in healthy individuals, yet reports in hematologic malignancy are limited. This case represents one of the few documented infections in this context, with details on diagnostic confirmation, antimicrobial susceptibility, and treatment outcomes. CASE PRESENTATION: A 37-year-old female with refractory diffuse large B-cell lymphoma developed Janibacter melonis bacteremia following autologous stem cell mobilization. The patient was immunocompromised as a result of prior therapy with a CD20 monoclonal antibody and intensive chemotherapy. She presented with fever and elevated inflammatory markers after consuming possibly spoiled kiwi fruit. Blood cultures identified Janibacter melonis, confirmed by 16 S ribosomal RNA gene sequencing. Antimicrobial susceptibility testing showed relatively weak activity of penicillins, cephalosporins, erythromycin, and clindamycin against the Janibacter melonis strain, whereas fluoroquinolones, aminoglycosides, tetracycline, glycopeptides, carbapenems, sulfonamides, rifampin, linezolid, and daptomycin had lower MICs; nitrofurantoin was inactive. The patient was treated successfully with cefoperazone-sulbactam, resulting in resolution of fever and normalization of inflammatory markers.
conclusionsThis case highlights the importance of considering rare infections in immunocompromised patients, especially those with hematologic malignancies. Prompt microbiological and molecular diagnosis, combined with targeted therapy, is essential for good outcomes. This report also provides useful insights for managing Janibacter melonis infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.